Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK.
South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK.
Int J Mol Sci. 2020 Aug 31;21(17):6290. doi: 10.3390/ijms21176290.
Inhibitors of the IL-6 signaling pathway, such as tocilizumab, are frequently administered for the treatment of immune diseases, e.g., rheumatoid arthritis and multicentric Castleman's disease. The aim of this systematic review and meta-analysis was to ascertain the effects of IL-6 pathway inhibitors on weight and body mass index (BMI). Using PRISMA guidelines, we systematically reviewed relevant articles from three databases (PubMed, OVID, EMBASE). A random effects model was used to estimate standardized mean change (SMCC). Ten studies with a total of 1531 patients were included in the meta-analysis for weight and ten studies with a total of 1537 patients were included in the BMI meta-analysis. The most commonly administered IL-6 pathway inhibitor was tocilizumab. IL-6 pathway inhibitors were associated with increases in weight (SMCC = 0.09, = 0.016, 95% CI [0.03, 0.14]) and BMI (SMCC = 0.10, = 0.0001, 95% CI [0.05, 0.15]). These findings suggest that the IL-6 pathway is involved in weight regulation. Modulating IL-6 signaling may be a potential future therapeutic avenue used as an adjunct for the treatment of disorders associated with weight changes, such as cancer cachexia and anorexia nervosa.
白细胞介素 6 信号通路抑制剂，如托珠单抗，常用于治疗免疫性疾病，如类风湿关节炎和多发性骨髓瘤性 Castleman 病。本系统评价和荟萃分析的目的是确定白细胞介素 6 通路抑制剂对体重和体重指数（BMI）的影响。我们使用 PRISMA 指南系统地检索了三个数据库（PubMed、OVID、EMBASE）中的相关文章。使用随机效应模型估计标准化均数差（SMCC）。共有 10 项研究，共 1531 名患者纳入体重荟萃分析，10 项研究，共 1537 名患者纳入 BMI 荟萃分析。最常使用的白细胞介素 6 通路抑制剂是托珠单抗。白细胞介素 6 通路抑制剂与体重增加相关（SMCC = 0.09， = 0.016，95%CI [0.03，0.14]）和 BMI（SMCC = 0.10， = 0.0001，95%CI [0.05，0.15]）。这些发现表明白细胞介素 6 通路参与了体重调节。调节白细胞介素 6 信号可能是一种潜在的未来治疗途径，可作为治疗与体重变化相关疾病的辅助手段，如癌症恶病质和神经性厌食症。
